3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
28
Carcinoma, Non-Small-Cell Lung
27
Colorectal Neoplasms
17
Esophageal Squamous Cell Carcinoma
14
Stomach Neoplasms
13
Squamous Cell Carcinoma of Head and Neck
13
Esophageal Neoplasms
12
Cholangiocarcinoma
10
Lung Neoplasms
9
Head and Neck Neoplasms
9
Uterine Cervical Neoplasms
8
Small Cell Lung Carcinoma
8
Triple Negative Breast Neoplasms
7
Rectal Neoplasms
7
Nasopharyngeal Carcinoma
6
Melanoma
5
Colonic Neoplasms
5
Recurrence
4
Pancreatic Neoplasms
4
Locally Advanced Rectal Cancer
4
Hodgkin Disease
4
Neoplasms
3
NSCLC
3
Lymphoma, Extranodal NK-T-Cell
3
Glioblastoma
3
Carcinoma, Transitional Cell
3
Biliary Tract Neoplasms
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Interventions
toripalimab
2
zanidatamab
1
tislelizumab
1
disitamab vedotin
1
Probiotics
1
Gemcitabine
1
Cisplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Muscle Invasive Bladder Cancer (MIBC)
×
tislelizumab
×
Clear all
NCT07296705
2025-12-22
HARBOR
Fujian Medical University Union Hospital
Phase 2
Recruiting
25 enrolled